Precision for Medicine announced a strategic partnership with SOPHiA GENETICS to enhance its biomarker discovery and precision medicine services for biopharma companies. This collaboration involves integrating the SOPHiA DDM™ Platform for biomarker discovery, clinical trial assays (CTAs), and advanced algorithms to expand clinical trial capabilities.
Through this partnership, Precision for Medicine will leverage SOPHiA DDM™'s AI-driven algorithms to analyze complex multimodal data, including genomic, radiomic, and clinical information. This capability aims to accelerate biomarker discovery, improve diagnostic capabilities, and identify appropriate patient populations for clinical trials, potentially reducing drug development costs by an estimated 20-30%.
Additionally, MSK-ACCESS® powered with SOPHiA DDM™, SOPHiA GENETICS' innovative liquid biopsy test, will be made available as a Precision for Medicine service for biopharma clients. This integrated approach offers a seamless solution for data analysis and clinical support, enabling biopharma companies to accelerate drug development and bring targeted therapies to market faster.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.